Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine.

Primary angioplasty is the best treatment of acute myocardial infarction but fails to achieve adequate myocardial reperfusion in 25% to 30% of patients, despite TIMI grade 3 flow. Drug treatment aimed at reducing the no-reflow phenomenon may improve myocardial salvage, thus preventing left ventricular remodeling. Our aim was to evaluate the impact of abciximab and adenosine on immediate angiographic results and on 6-month left ventricular remodeling.
Ninety consecutive patients undergoing primary angioplasty with coronary stenting were randomized in a sequential alternating fashion to standard abciximab treatment (ABCX) group, intracoronary adenosine distal to the occlusion (ADO) group, or neither (CTRL) group. All patients underwent a clinical and echocardiographic follow-up at 1 and 6 months. The primary end point was the prevalence of 6-month left ventricular remodeling.
Baseline clinical, echocardiographic, and angiographic characteristics were similar. Mean final corrected TIMI frame count was 17 +/- 9, 16 +/- 12, and 23 +/- 11 frames in ABCX, ADO, and CTRL patients, respectively (P = .002). Angiographic no-reflow was observed in 7%, 13%, and 17% of ABCX, ADO, and CTRL patients, respectively (P > .20). At 6 months, left ventricular remodeling occurred in 7%, 30%, and 30% of ABCX, ADO, and CTRL patients, respectively (P = .045), with a percent increase in end-diastolic volume of 5% +/- 13%, 15% +/- 15%, and 12% +/- 18% (P = .04).
During primary angioplasty, abciximab enhances myocardial reperfusion, translating into a reduced incidence of 6-month left ventricular remodeling. In contrast, adenosine administration improves angiographic results but does not prevent left ventricular remodeling.
AuthorsAnna S Petronio, Marco De Carlo, Nicola Ciabatti, Giovanni Amoroso, Ugo Limbruno, Caterina Palagi, Vitantonio Di Bello, Maria F Romano, Mario Mariani
JournalAmerican heart journal (Am Heart J) Vol. 150 Issue 5 Pg. 1015 (Nov 2005) ISSN: 1097-6744 [Electronic] United States
PMID16290987 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Adenosine
  • abciximab
  • Adenosine (administration & dosage)
  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal (therapeutic use)
  • Coronary Vessels
  • Female
  • Humans
  • Immunoglobulin Fab Fragments (therapeutic use)
  • Male
  • Middle Aged
  • Ventricular Remodeling

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: